Mithra Signs LSA for Commercialization of Estelle® and Myring™ in Israel

/in , , /by

Mithra grants exclusive license to Dexcel Pharma for commercialization of its two leading contraceptive products in Israel Dexcel Pharma is Israel’s largest private pharmaceutical company Production at the Mithra CDMO facility in Belgium Liege, Belgium, 20 August 2019 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it […]

Read more →

Mithra obtains crucial additional Estelle® patent in Japan

/in , /by

Estelle®, Mithra’s oral contraceptive product candidate, has been granted a key patent for the dysmenorrhea indication in Japan, a four times larger market than the contraceptive one. Important milestone for the commercialization of Estelle® by Fuji Pharma in Japan and ASEAN, representing a total attractively priced market of EUR 400 million annual sales. Thanks to a solid […]

Read more →

Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs

/in , , , /by

Strengthening of management team with key appointments of Chief Scientific Officer and Plant Manager, to support the strategy execution of Mithra CDMO Consolidation of R&D and manufacturing teams with 30% increase in highly qualified staff since the beginning of the year Donesta® and PeriNesta® Phase III studies ready to begin, pending approval by authorities Launch […]

Read more →

Mithra Signs LSA for Commercialization of Myring™ in Germany, the biggest market in Europe

/in , /by

Mithra grants exclusive license to Hormosan for commercialization of vaginal contraceptive ring in Germany Germany is the largest European market in terms of volumes, with 3 million vaginal rings sold per year Agreement follows licensing deals for Myring™ with market leaders in the U.S., Europe, Russia, Australia, Middle East, Latin and South America Liege, Belgium, […]

Read more →

Tibelia®, First Tibolone-Based Hormone Therapy Approved in Canada

/in , /by

The Canadian Health authorities have granted the Marketing Authorization for Tibelia®, the company’s tibolone-based product for use in Hormone Therapy (HT). First tibolone-based hormone treatment to be available in Canada, offering a true new option for women with a proven efficacy, tolerability and safety profile The introduction of Tibelia® in Canada plays a crucial role […]

Read more →

Information on the Total Number of Voting Rights (Denominator)

/in , /by

Liege, Belgium, 29 April 2019 – 17:45 CEST – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 24,750 new shares on 24 April 2019 for an amount of EUR 84,690 as the result of the […]

Read more →

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Latin and South America

/in , /by

Mithra grants exclusive 10-year license to Megalabs for commercialization of vaginal contraceptive ring in Argentina, Paraguay and the Dominican Republic Product to be manufactured at Mithra CDMO facility in Belgium Agreement follows licensing deals for Myring™ with international market leaders in the U.S., Europe, Russia, Australia, Middle East and Chile Liege, Belgium, 25 April 2019 […]

Read more →

Mithra announces new agreement with GSP for development of an additional injectable

/in , /by

Agreement with Generic Specialty Pharma (GSP), a leading generics player, for development and supply of a fifth hormonal injectable. Expansion of Mithra CDMO’s portfolio of activities, confirming its profile as a unique industrial partner in the development and production of a complete range of specialized medical products and devices. Liege, Belgium, 18 April 2019 – […]

Read more →

Mithra Releases 2018 Annual Report and Invitation to its General Shareholders’ Meeting

/in /by

Liege, Belgium, 8 April 2019 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces the publication of its 2018 Annual Report and the invitation to its Ordinary and Extraordinary General Shareholders’ meeting. Annual Report The Annual Report which outlines Mithra’s achievements in 2018 includes the following information: Overview of […]

Read more →

Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle®

/in , /by

Mithra wins the Essenscia Innovation Award, the most prestigious prize for industrial innovation in Belgium Jury of experts recognize the major breakthrough and worldwide potential of this new generation contraceptive pill Capping more than 20 years of research and development, this award was presented by her Royal Highness, the Princess Astrid, during a ceremony at […]

Read more →